Overview

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

Status:
Active, not recruiting

Trial end date:
2022-07-08

Target enrollment:

Participant gender:

Summary

This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)

Phase:

Phase 1

Details

Lead Sponsor:

Sparrow Pharmaceuticals

Treatments:

Anti-Inflammatory Agents
Cortisone
Glucocorticoids